Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was down 6.9% during mid-day trading on Tuesday . The stock traded as low as $2.41 and last traded at $2.44. Approximately 1,797,115 shares traded hands during mid-day trading, an increase of 91% from the average daily volume of 941,566 shares. The stock had previously closed at $2.62.

Several equities research analysts have issued reports on CPRX shares. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research note on Monday, May 22nd. Piper Jaffray Companies set a $6.00 price target on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $5.00 price target on shares of Catalyst Pharmaceuticals in a research note on Tuesday. Finally, Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Catalyst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $4.90.

The stock’s market cap is $213.08 million. The firm has a 50-day moving average of $2.83 and a 200-day moving average of $2.19.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Equities research analysts predict that Catalyst Pharmaceuticals, Inc. will post ($0.23) earnings per share for the current fiscal year.

In other news, insider Patrick J. Mcenany acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was bought at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the insider now owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.79% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in CPRX. Nationwide Fund Advisors bought a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $111,000. New York State Common Retirement Fund bought a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $114,000. Oxford Asset Management boosted its position in shares of Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 34,181 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after acquiring an additional 2,404 shares during the period. Finally, State of Wisconsin Investment Board bought a new position in shares of Catalyst Pharmaceuticals in the second quarter valued at approximately $149,000. Institutional investors own 40.20% of the company’s stock.

WARNING: This piece of content was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/07/catalyst-pharmaceuticals-inc-cprx-trading-down-6-9.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.